Suven Pharma Secures DoP Approval for Cohance Lifesciences Merger
Deal News | Apr 26, 2025 | EIN
Suven Pharmaceuticals, backed by Advent International, has received the final approval from the Department of Pharmaceuticals (DoP) for its upcoming merger with Cohance Lifesciences. As per the approved Scheme of Amalgamation, the merger will take effect on May 1, 2025, once all necessary conditions are fulfilled. The merged entity will operate under the name Cohance Lifesciences Limited, concentrating on high-growth areas like Antibody-Drug Conjugates (ADCs) and oligonucleotides. With this strategic integration, Suven Pharmaceuticals aims to deepen customer partnerships and improve execution across the value chain to achieve its ambition of US$1 billion in revenue through organic growth and acquisitions. The National Company Law Tribunal (NCLT) had previously sanctioned the amalgamation scheme, setting a Record Date of May 8, 2025, for determining eligible shareholders who will receive equity shares as per the share exchange ratio.
Sectors
- Pharmaceuticals
- Private Equity
Geography
- India – Both Suven Pharmaceuticals and Cohance Lifesciences are headquartered and operate in India, making it a significant geography for this transaction.
Industry
- Pharmaceuticals – The article is primarily about a merger involving Suven Pharmaceuticals and Cohance Lifesciences, both operating in the pharmaceuticals industry.
- Private Equity – Advent International, a private equity firm, is backing Suven Pharmaceuticals, indicating the private equity sector's involvement in this merger.
Financials
- US$1 billion – The revenue ambition of the merged entity Suven Pharmaceuticals and Cohance Lifesciences aiming to achieve through organic growth and strategic acquisitions.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Suven Pharmaceuticals | Target Company | Company | A contract development and manufacturing organization (CDMO) backed by Advent International, involved in the merger with Cohance Lifesciences. |
| Cohance Lifesciences | Selling Company | Company | The pharmaceutical company merging with Suven Pharmaceuticals, focusing on high-growth modalities. |
| Advent International | Private Equity Backer | Company | A global private equity firm backing Suven Pharmaceuticals. |
| Department of Pharmaceuticals (DoP) | Regulatory Authority | Government | The Indian government department that granted approval for the merger. |
| National Company Law Tribunal (NCLT) | Legal Authority | Government | Provided sanction for the scheme of amalgamation between Suven Pharmaceuticals and Cohance Lifesciences. |